Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

88 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Genetic and environmental factors as predictors of disease severity and extent at time of diagnosis in an inception cohort of inflammatory bowel disease, Copenhagen County and City 2003-2005.
Vind I, Riis L, Jespersgaard C, Jess T, Knudsen E, Pedersen N, Elkjaere M, Hansen TS, Andersen IB, Paerregaard A, Bondesen S, Locht H, Larsen SO, Moesgaard F, Bendtsen F, Andersen PS, Munkholm P; DCCD study group. Vind I, et al. Among authors: hansen ts. J Crohns Colitis. 2008 Jun;2(2):162-9. doi: 10.1016/j.crohns.2008.01.004. Epub 2008 Mar 4. J Crohns Colitis. 2008. PMID: 21172207
Infliximab for inflammatory bowel disease in Denmark 1999-2005: clinical outcome and follow-up evaluation of malignancy and mortality.
Caspersen S, Elkjaer M, Riis L, Pedersen N, Mortensen C, Jess T, Sarto P, Hansen TS, Wewer V, Bendtsen F, Moesgaard F, Munkholm P; Danish Crohn Colitis Database. Caspersen S, et al. Among authors: hansen ts. Clin Gastroenterol Hepatol. 2008 Nov;6(11):1212-7; quiz 1176. doi: 10.1016/j.cgh.2008.05.010. Epub 2008 Oct 9. Clin Gastroenterol Hepatol. 2008. PMID: 18848503
Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial.
Dejgaard TF, Frandsen CS, Hansen TS, Almdal T, Urhammer S, Pedersen-Bjergaard U, Jensen T, Jensen AK, Holst JJ, Tarnow L, Knop FK, Madsbad S, Andersen HU. Dejgaard TF, et al. Among authors: hansen ts. Lancet Diabetes Endocrinol. 2016 Mar;4(3):221-232. doi: 10.1016/S2213-8587(15)00436-2. Epub 2015 Dec 3. Lancet Diabetes Endocrinol. 2016. PMID: 26656289 Clinical Trial.
Efficacy and safety of the glucagon-like peptide-1 receptor agonist liraglutide added to insulin therapy in poorly regulated patients with type 1 diabetes--a protocol for a randomised, double-blind, placebo-controlled study: the Lira-1 study.
Dejgaard TF, Knop FK, Tarnow L, Frandsen CS, Hansen TS, Almdal T, Holst JJ, Madsbad S, Andersen HU. Dejgaard TF, et al. Among authors: hansen ts. BMJ Open. 2015 Apr 2;5(4):e007791. doi: 10.1136/bmjopen-2015-007791. BMJ Open. 2015. PMID: 25838513 Free PMC article. Clinical Trial.
88 results